Once versus twice daily amikacin in neonates: Prospective study on toxicity

Journal of Paediatrics and Child Health

Volumn 35, Issue 3, 1999, Pages 283-286

  Kotze, A ^a,b   Bartel, P R ^a   De Sommers, K ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Department of Pharmacology ^*  (South Africa)

Author keywords

Amikacin; Neonate; Once daily; Toxicity

Indexed keywords

AMIKACIN; CREATINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MECONIUM ASPIRATION; NEWBORN; OTOTOXICITY; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TOXICITY TESTING;

AMIKACIN; ANTI-BACTERIAL AGENTS; CREATININE; EVOKED POTENTIALS, AUDITORY; FEMALE; HEARING; HUMANS; INFANT, NEWBORN; KIDNEY FUNCTION TESTS; KIDNEY GLOMERULUS; MALE;

EID: 0033017346     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.1999.00352.x     Document Type: Article

References (31)

1. 1 Lane AZ, Wright GE, Blair DC. Ototoxicity and nephrotoxicity of amikacin. Am. J. Med. 1997; 62: 911-8.
2. 2 Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once versus twice daily amikacin dosing in critically ill adult and paediatric patients. J. Antimicrob. Chemother. 1991; 28: 753-64.
3. 3 Finitzo-Hieber TF, McCracken GH, Brown KC. Prospective control evaluation of auditory functions in neonates given netilmicin or amikacin. J. Pediatr. 1985; 106: 129-36.
4. 4 Katoyanides GJ. Aminoglycoside nephrotoxicity. In Schrier RW, Gottschalk CW, eds. Diseases of the kidney. Boston, Little Brown, 1993; 1131-64.
5. 5 Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann. Intern. Med. 1996; 124: 717-25.
6. 6 Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin. Pharmocokinet. 1994; 27: 32-48.
7. 7 Freeman CD, Strayer AH. Mega-analysis of meta-analysis: An examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy. 1996; 16: 1093-102.
8. 8 Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J. Antimicrob. Chemother. 1996; 37: 645-63.
9. 9 Langhendries JP, Battisti O, Bertrand JM et al. Once-a-day administration of amikacin in neonates: Assessment of nephrotoxicity and ototoxicity. Dev. Pharmacol. Ther. 1993; 20: 220-30.
10. 10 Ibrahim S, Langhendries JP, Bernard A, Tulkens PM. Urinary phospholipids excretion in neonates treated with amikacin. Int. J. Clin. Pharm. Res. 1994; 14: 149-56.
11. 11 Picton TW, Durieux-Smith A. Auditory evoked potentials in the assessment of hearing. Neurol. Clin. 1988; 6: 791-808.
12. 12 Steyn AGW, Smit CF, Du Toit SHC, Strasheim C. Modem Statistics in Practice, 4th. edn. Pretoria, JL van Schaik, 1994; 678.
13. 13 Andronikou S, Giapros VI, Cholevas VI, Papadopoulou ZL. Effect of aminoglycoside therapy on renal function in fullterm infants. Pediatr. Nephrol. 1996; 10: 766-8.
14. 14 Bernard PA. Freedom from ototoxicity in aminoglycoside treated neonates: A mistaken notion. Laryngoscope 1981; 91: 1985-94.
15. 15 Fee WE. Aminoglycoside ototoxicity in the human. Laryngoscope 1980; 90: S1-19.
16. 16 Mattie H, Craig, WA Pechére, JC. Determinants of efficacy and toxicity of aminoglycosides. J. Antimicrob. Chemother. 1989; 24: 281-93.
17. 17 Salamy A, Mendelson T, Tooley WH. Developmental profiles for the brainstem auditory evoked potential. Early Hum. Dev. 1982; 6: 331-9.
18. 18 Rudd PT, Hughes EA, Placzek MM, Hodes DT. Reference ranges for plasma creatinine during the first month of life. Arch. Dis. Child. 1983; 58: 212-5.
19. 19 Gordjani N, Burghard R, Leititis JU, Brandis M. Serum creatinine and creatinine clearance in healthy neonates and prematures during the first 10 days of life. Eur. J. Pediatr. 1988; 148: 143-5.
20. 20 Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J. Pediatr. 1984; 104: 849-54.
21. 21 Moore RD, Lietman PS, Craig RS. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 1987; 155: 93-9.
22. 22 Craig WA, Vogelman B. The postantibiotic effect. Ann. Intern. Med. 1987; 106: 900-2.
23. 23 Adelman RD, Halsted CC, Jordan GW, Russo J. Use of urinary enzyme activities in the early detection of aminoglycoside nephrotoxicity. A study in children and adults receiving gentamicin or netilmicin. Proc. West. Pharmacol. Soc. 1981; 24: 261-4.
24. 24 Adelman RD, Wirth F, Rubio T. A controlled study of nephrotoxicity of mezlocillin and gentamicin plus ampicillin in the neonate. J. Pediatr. 1987; 111: 888-93.
25. 25 Tessin I, Bergmark J, Hiesche K, Jagenburg R, Trollfors B. Renal function of neonates during gentamicin treatment. Arch. Dis. Child. 1982; 57: 758-60.
26. 26 Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM. Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch. Dis. Child. 1976; 51: 875-8.
27. 27 Wagner BP, Pfenninger J. Once daily dosing of netilmicin in neonatal and pediatric intensive care. Intensive Care Med. 1994; 20: 365-7.
28. 28 Hayani KC, Hatzopoulos FK, Frank AL et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J. Pediatr. 1997; 131: 76-80.
29. 29 Luft FC. Clinical significance of renal changes engendered by aminoglycosides in man. J. Antimicrob. Chemother. 1984; 13: S23-8.
30. 30 Giapros VI, Andronikou S, Cholevas VI, Papadopoulou ZL. Renal function in premature infants during aminogiycoside therapy. Pediatr. Nephrol. 1995; 9: 163-6.
31. 31 Brummet RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989; 33: 797-800.